CHICAGO, Aug. 11 (Xinhua) -- A novel precision medicine approach enhanced by artificial intelligence (AI) has laid the groundwork for what could be the first biomedical screening and intervention tool for a subtype of autism, according to a new study.
The subtype of the disorder studied by researchers from Northwestern University (NU), Ben Gurion University, Harvard University and the Massachusetts Institute of Technology is known as dyslipidemia-associated autism, which represents 6.55 percent of all diagnosed autism spectrum disorders in the United States.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
